Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Overview | 10 | 1 |
| Therapeutics Development | 11 | 4 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Products under Development by Stage of Development | 11 | 1 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Products under Development by Therapy Area | 12 | 1 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Products under Development by Indication | 13 | 2 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Pipeline Products Glance | 15 | 2 |
| Late Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Products under Development by Companies | 17 | 7 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Products under Development by Universities/Institutes | 24 | 2 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Therapeutics Assessment | 26 | 5 |
| Assessment by Monotherapy/Combination Products | 26 | 1 |
| Assessment by Mechanism of Action | 27 | 1 |
| Assessment by Route of Administration | 28 | 1 |
| Assessment by Molecule Type | 29 | 2 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Companies Involved in Therapeutics Development | 31 | 19 |
| AbbVie Inc. | 31 | 2 |
| Advinus Therapeutics Ltd | 33 | 1 |
| ArQule, Inc. | 34 | 1 |
| BeiGene, Ltd. | 35 | 1 |
| Bristol-Myers Squibb Company | 36 | 1 |
| Celgene Corporation | 37 | 1 |
| CrystalGenomics, Inc. | 38 | 1 |
| Genentech, Inc. | 39 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 40 | 1 |
| LSK BioPartners, Inc. | 41 | 1 |
| Merck KGaA | 42 | 1 |
| Ono Pharmaceutical Co., Ltd. | 43 | 1 |
| Pharmacyclics, Inc. | 44 | 1 |
| Principia Biopharma Inc. | 45 | 1 |
| Redx Pharma Plc | 46 | 1 |
| Simcere Pharmaceutical Group | 47 | 1 |
| Sunesis Pharmaceuticals, Inc. | 48 | 1 |
| Takeda Pharmaceutical Company Limited | 49 | 1 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Drug Profiles | 50 | 67 |
| acalabrutinib Drug Profile | 50 | 4 |
| Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia Drug Profile | 54 | 1 |
| ARQ-531 Drug Profile | 55 | 1 |
| BGB-3111 Drug Profile | 56 | 2 |
| CG-026806 Drug Profile | 58 | 1 |
| CG-036806 Drug Profile | 59 | 1 |
| Drug to Inhibit BTK for Undisclosed Indications Drug Profile | 60 | 1 |
| EBI-1266 Drug Profile | 61 | 1 |
| EBI-1367 Drug Profile | 62 | 1 |
| HCI-1401 Drug Profile | 63 | 1 |
| HCI-1684 Drug Profile | 64 | 1 |
| HM-71224 Drug Profile | 65 | 1 |
| ibrutinib Drug Profile | 66 | 25 |
| M-2951 Drug Profile | 91 | 1 |
| M-7583 Drug Profile | 92 | 1 |
| ONO-4059 Drug Profile | 93 | 2 |
| PLS-123 Drug Profile | 95 | 1 |
| PNQ-154 Drug Profile | 96 | 1 |
| PNQ-849 Drug Profile | 97 | 1 |
| PRN-1008 Drug Profile | 98 | 2 |
| PRN-473 Drug Profile | 100 | 1 |
| RDX-002 Drug Profile | 101 | 1 |
| RG-7845 Drug Profile | 102 | 1 |
| Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis Drug Profile | 103 | 1 |
| Small Molecule to Inhibit Bruton Tyrosine Kinase for Inflammation Drug Profile | 104 | 1 |
| Small Molecule to Inhibit BTK for Immunology Drug Profile | 105 | 1 |
| Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer Drug Profile | 106 | 1 |
| Small Molecule to Inhibit BTK for Oncology Drug Profile | 107 | 1 |
| Small Molecules to Inhibit BTK for Oncology Drug Profile | 108 | 1 |
| Small Molecules to Inhibit BTK for Rheumatoid Arthritis Drug Profile | 109 | 2 |
| SNS-062 Drug Profile | 111 | 2 |
| spebrutinib besylate Drug Profile | 113 | 2 |
| TAK-020 Drug Profile | 115 | 1 |
| X-022 Drug Profile | 116 | 1 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Dormant Projects | 117 | 3 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Discontinued Products | 120 | 1 |
| Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Featured News &Press Releases | 121 | 16 |
| Jun 06, 2016: AbbVie Builds Upon Robust Body of IMBRUVICA (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology Annual Meeting | 121 | 2 |
| Jun 01, 2016: NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund | 123 | 1 |
| May 31, 2016: Janssen's IMBRUVICA (ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia | 124 | 1 |
| May 24, 2016: REDX PHARMA: Proof of concept with key oncology lead | 125 | 1 |
| May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016 | 125 | 1 |
| May 18, 2016: Janssen to Present Data on Ibrutinib at the 2016 American Society of Clinical Oncology Annual Meeting | 126 | 1 |
| May 12, 2016: Health Canada Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenstroms Macroglobulinemia | 127 | 1 |
| May 09, 2016: U.S. FDA Expands IMBRUVICA (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia and New Indication for Small Lymphocytic Lymphoma Patients | 128 | 2 |
| Apr 29, 2016: European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients | 130 | 1 |
| Apr 29, 2016: Janssen's IMBRUVICA (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients | 131 | 1 |
| Mar 23, 2016: Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 | 132 | 1 |
| Mar 14, 2016: Diplomat Now Dispensing IMBRUVICA as First-Line Therapy for Chronic Lymphocytic Leukemia | 132 | 1 |
| Mar 07, 2016: BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111 | 133 | 1 |
| Mar 04, 2016: U.S. FDA Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia | 133 | 2 |
| Feb 25, 2016: Acalabrutinib recommended for orphan drug designation in Europe for three indications | 135 | 2 |
| Appendix | 137 | 2 |
| Methodology | 137 | 1 |
| Coverage | 137 | 1 |
| Secondary Research | 137 | 1 |
| Primary Research | 137 | 1 |
| Expert Panel Validation | 137 | 1 |
| Contact Us | 137 | 1 |
| Disclaimer | 138 | 1 |